Fulgent Genetics

Enhanced Whole Genome Sequencing Will Open New Global Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 Mar 25

Updated

10 Dec 25

Views

32

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

50.5%

7D

1.7%

Loading

1Y

50.5%

7D

1.7%

You can edit this narrative until Dec 11 5:05 AM. Then, changes will post as Updates.

Author's Valuation

US$33.6718.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 10 Dec 25

FLGT: Raised 2025 Guidance And Trial Progress Will Support Bullish Outlook

Analysts maintained their price target on Fulgent Genetics at approximately 33.67 dollars, citing largely unchanged expectations for revenue growth and valuation multiples, despite a modest reduction in projected profit margins. What's in the News Raised full year 2025 earnings guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, signaling improved visibility into core business trends (company guidance) Reported preliminary phase 2 clinical data for FID-007 in combination with cetuximab as a second line treatment for recurrent or metastatic head and neck squamous cell carcinoma, with results to be presented at the ESMO 2025 meeting in Berlin (company clinical update) Highlighted that FID-007 nanoparticles are smaller than solvent based PTX micelles, which enables deeper tumor penetration, slower clearance, and higher intratumoral accumulation due to the enhanced permeability and retention effect (company clinical update) Valuation Changes Fair Value Estimate remained unchanged at approximately 33.67 dollars per share, indicating no material shift in intrinsic value assumptions.

Shared on 26 Nov 25

Fair value Increased 25%

FLGT: Earnings Outlook And Clinical Data May Define Performance In 2025

Narrative Update on Fulgent Genetics Analyst Price Target Analysts have raised their price target for Fulgent Genetics from $27.00 to $33.67. This change is attributed to improved revenue growth and higher forecasted profit margins.

Shared on 11 Nov 25

Fair value Increased 6.58%

FLGT: Full-Year Guidance And Early Clinical Data Will Shape 2025 Outlook

Analysts have raised their price target for Fulgent Genetics from $25.33 to $27.00, citing slightly improved profit margin projections as well as updated market expectations. What's in the News Fulgent Genetics raised its earnings guidance for the full year 2025, expecting revenue of approximately $325 million and improving its EPS guidance to a GAAP loss of approximately $1.70 per share.

Shared on 06 Aug 25

Fair value Increased 12%

Fulgent Genetics’ fair value has been revised upward, primarily reflecting improved consensus revenue growth forecasts and a higher future P/E multiple, with the analyst price target rising from $22.67 to $25.33. What's in the News Fulgent Genetics expects core revenue of approximately $320 million for full year 2025.

Shared on 01 May 25

Fair value Increased 11%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$33.67

18.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

9.43%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$22.91m

Earnings '28

x

55.73x

PE Ratio '28

=

US$1.28b

Market Cap '28

US$1.28b

Market Cap '28

/

31.16m

No. shares '28

=

US$40.98

Share Price '28

US$40.98 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$33.49

Fair Value '25